Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells - PubMed (original) (raw)
Review
Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells
Nicholas Chiorazzi. Best Pract Res Clin Haematol. 2007 Sep.
Abstract
Chronic lymphocytic leukemia (CLL) results from an accumulation of abnormal B cells due to an imbalance between birth and death rates such that the former exceeds the latter. This imbalance can occur as a result of increased birth, decreased death, or a combination of the two. CLL has long been considered a disease in which cell accumulation results from decreased death, due to a genetic defect, with minimal birth of the leukemic clone. This view was promulgated when experimental options were limited and observations in vivo and in vitro were less precise--e.g. CLL cells appeared as resting lymphocytes by light microscopy and responded poorly to mitogens (primarily T-cell mitogens)--at a time when T- and B-cell discrimination was not well appreciated. However, recent studies using more sophisticated measures suggest that the initial characterization of CLL biology needs re-evaluation. Using a safe, non-radioactive in-vivo labeling method that permits the determination of CLL-cell birth rates, we have directly documented that a small fraction of the clone (approximately 0.1-1.75%), i.e., between approximately 1x10(9) and 1x10(12) cells are born each day in all patients studied. With this value, we calculated death rates of between 0 and 1x10(12) per day of leukemic cells from individual patients. Thus the dynamic interplay between birth and death that characterizes other leukemias and lymphomas applies to CLL. Therefore, CLL is a disease of both proliferation and accumulation in which a homeostatic balance exists in patients with stable lymphocyte counts or an imbalance exists in patients with rising lymphocyte counts.
Similar articles
- Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.
De Fanis U, Romano C, Dalla Mora L, Sellitto A, Guastafierro S, Tirelli A, Bresciano E, Giunta R, Lucivero G. De Fanis U, et al. Oncol Rep. 2003 May-Jun;10(3):653-8. Oncol Rep. 2003. PMID: 12684639 - The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells.
de Vries JF, Falkenburg JH, Willemze R, Barge RM. de Vries JF, et al. Haematologica. 2006 Jul;91(7):912-9. Haematologica. 2006. PMID: 16818278 - In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow.
van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JA, Vrisekoop N, Ackermans MA, Ruiter AF, Wittebol S, Eldering E, van Oers MH, Tesselaar K, Kersten MJ, Miedema F. van Gent R, et al. Cancer Res. 2008 Dec 15;68(24):10137-44. doi: 10.1158/0008-5472.CAN-08-2325. Cancer Res. 2008. PMID: 19074880 - Sézary syndrome coexisting with B-cell chronic lymphocytic leukemia: case report and review of the literature.
Karsai S, Hou JS, Telang G, Kantor GR, Nowell PC, Vonderheid EC. Karsai S, et al. Dermatology. 2008;216(1):68-75. doi: 10.1159/000109362. Dermatology. 2008. PMID: 18032903 Review. - B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens.
Chiorazzi N, Hatzi K, Albesiano E. Chiorazzi N, et al. Ann N Y Acad Sci. 2005 Dec;1062:1-12. doi: 10.1196/annals.1358.002. Ann N Y Acad Sci. 2005. PMID: 16461783 Review.
Cited by
- The novel NF-κB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia.
Kanduri M, Tobin G, Aleskog A, Nilsson K, Rosenquist R. Kanduri M, et al. Blood Cancer J. 2011 Mar;1(3):e12. doi: 10.1038/bcj.2011.9. Epub 2011 Mar 25. Blood Cancer J. 2011. PMID: 22829125 Free PMC article. - Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia.
Allain EP, Rouleau M, Le T, Vanura K, Villeneuve L, Caron P, Turcotte V, Lévesque E, Guillemette C. Allain EP, et al. Front Oncol. 2019 Jul 4;9:606. doi: 10.3389/fonc.2019.00606. eCollection 2019. Front Oncol. 2019. PMID: 31334126 Free PMC article. - Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.
Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Ding W, et al. Br J Haematol. 2009 Nov;147(4):471-83. doi: 10.1111/j.1365-2141.2009.07868.x. Epub 2009 Sep 8. Br J Haematol. 2009. PMID: 19751240 Free PMC article. - Formaldehyde induces micronuclei in mouse erythropoietic cells and suppresses the expansion of human erythroid progenitor cells.
Ji Z, Li X, Fromowitz M, Mutter-Rottmayer E, Tung J, Smith MT, Zhang L. Ji Z, et al. Toxicol Lett. 2014 Jan 13;224(2):233-9. doi: 10.1016/j.toxlet.2013.10.028. Epub 2013 Nov 1. Toxicol Lett. 2014. PMID: 24188930 Free PMC article. - Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.
Karabon L, Partyka A, Jasek M, Lech-Maranda E, Grzybowska-Izydorczyk O, Bojarska-Junak A, Pawlak-Adamska E, Tomkiewicz A, Robak T, Rolinski J, Frydecka I. Karabon L, et al. Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):137-145. doi: 10.1007/s00005-016-0430-x. Epub 2016 Dec 8. Arch Immunol Ther Exp (Warsz). 2016. PMID: 27933341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources